Skip Navigation


NDT Advance Access originally published online on December 10, 2008
Nephrology Dialysis Transplantation 2009 24(3):701-702; doi:10.1093/ndt/gfn695
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/3/701    most recent
gfn695v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kalaitzidis, R.
Right arrow Articles by Bakris, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalaitzidis, R.
Right arrow Articles by Bakris, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Should nephrologists use beta-blockers? A perspective

Rigas Kalaitzidis and George Bakris

Department of Medicine, Hypertensive Diseases Unit, University of Chicago School of Medicine, Chicago, IL, USA

Correspondence and offprint requests to: George Bakris, University of Chicago School of Medicine, 5841 S. Maryland Ave MC 1027, Chicago, IL 60637, USA. Tel: +1-773-702-7936; Fax: +1-773-834-0486; E-mail: gbakris@gmail.com

Keywords: beta-blockers; dialysis; hypertension; kidney; mortality

The first 10% of the full text of this article appears below.

Given the high prevalence of cardiovascular disease in people with chronic kidney disease (CKD) and the clear benefits of mortality reduction observed for most β–blockers in clinical trials, they are relatively underused in CKD patients [1,2]. The rationale for use of β-blockers in patients with CKD is reviewed in detail elsewhere [2,3] but is summarized in this editorial.

Alterations in β- and {alpha}-receptor responsiveness are associated with sympathetic over-activity in CKD. This increased sympathetic activity is involved in the genesis of hypertension, and contributes to cardiac complications seen in CKD [2,3]. The contribution of the sympathetic nervous system to nephropathy progression is documented in sub-totally nephrectomized rats where non-hypotensive doses of β-blockers ameliorate development of glomerulosclerosis . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?